Biopharma Group

Oroxcell is an independent research organization (CRO) offering research services assessing the safety, toxicity and efficacy of active ingredients and finished formulations.

Specialized in in-vitro testing, particularly in 3D Human Models, Oroxcell is developing its business on two fronts:

• Safety & efficacy testing: From screening to GLP Compliant studies, we provide well established In-vitro platform, 2D and 3D models, for performing routine and regulatory safety testing, ADME (Absorption, Distribution, Metabolism, and Elimination) and Toxicity (sensitization, phototoxicity and genotoxicity) tests, bioanalytical studies, for evaluating pharmaceuticals, medical devices, cosmetics, nutraceuticals, home care and chemical products.

• Research & Innovation: Oroxcell provides a wide range of services including R&D project management and technical support, international consortium setup and management and regulatory & toxicology consulting.
We assist you in selecting or developing the best alternative testing methods for your safety and efficacy issues.

Oroxcell has been certified GLP compliant (Grade A, the highest grade) since 2011 by the French National Medicines and Cosmetics Safety Agency, ANSM.


Website: http://www.oroxcell.com
Contact: contact@oroxcell.com

We are a privately held Italian company founded in 1973. We are a fully integrated manufacturer of Cephalosporin, Carbapenem and Penicillin APIs as well as Finished Dosage Formulations (Solid and Injectable). We export our products to MORE than 100 countries all over the world.

Our production sites, most of them regularly inspected by EUROPEAN AND USA AUTHORITIES (FDA), have strict Quality Standards and our R&D Know-how make us a leading company.

Our Commitment: to work in the present while concentrating on the future, because on markets where research and technology are factors of primary importance, we have always to be on the cutting edge of progress in the development of production.

From this premise emerge Acs Dobfar's six key factors for success:
- High Quality Products
- Innovative Production Processes
- High Technology
- Market Diversification
- Customer Support
- Environment Respect

DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization, active in the development, production and sales of pharmaceutical products.
The company’s manufacturing plant in Krioneri of Attica, is the largest in Southeastern Europe and one of the world’s largest, with state of the art facilities of 57,000 m2, including and a very hi- tech Quality Control Laboratory of 2,000+ m2.
DEMO S.A. is one of the major pharmaceutical manufacturers in Greece with a strong presence in the hospital market, ranking first among all the Greek pharmaceutical companies in terms of units sold. Our product portfolio includes injectable generic pharmaceutical formulations from several therapeutic categories: Injectable products of all forms such us Liquid injectables in glass ampoules, vials & bottles, sterile powders and freeze – dried formulations, Lyophilised products, Emulsions, Penems, Penicillins, Cephalosporins, Solutions & Suspensions for nebulization, medical devises and food supplements. It also performs an extensive R&D program for controlled release injectables.

DEMO S.A. has faithfully served its export orientation over the last years, with its sales network expanding to Europe, Asia, Africa,the Middle East, South America and Oceania. The company exports 84% of its annual production and is rapidly expanding its range of products to international markets.
Our company is a registered supplier of the United Nations, UNICEF, World Health Organization, MSF and the International Red Cross. With 2500+ approved products in 85 countries worldwide and 970 employees, DEMO aims to reliably meet the needs of the market in Greece and internationally. Our cutting edge production facilities allow us to offer our partners services such as:
• Worldwide distribution opportunities
• Out-licensing services
• Contract manufacturing operations.

Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.

What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.

How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.

Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.

Dossiers ready to file:
- Rasagiline (Parkinson’s diseases)
- Alprazolam (Anxiolytic)
- Deflazacort (Corticosteroid)
- Modafinil (Narcolepsy)
- Sildenafil (Erectil Dysfunction)
- Pioglitazone (Diabetes)
- Rivastigmine (Alzheimer diseases)

Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.

Please, contact us on generics@efarmes.es

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES

Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market.

●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration.

Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization.

●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies.

« Patients are central to our approaches »

Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.